Loading
A phase 1 trial of NG-350A run by Akamis Bio, completed.
First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody) is a phase 1 interventional study registered as NCT03852511 by Akamis Bio, with 28 participants enrolled, started 2019-02-19, primary completion reached 2022-02-04. Conditions recorded: Metastatic Cancer, Epithelial Tumor. Interventions recorded: NG-350A.
Shares NG-350A, Akamis Bio and the tag pipeline.
Shares NG-350A, Akamis Bio and the tag pipeline.
Shares Akamis Bio and the tag pipeline.
Shares NG-350A, Akamis Bio.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/